Introduction to Syros Pharmaceuticals Inc. (350+ Words)

Syros Pharmaceuticals Inc., headquartered in Cambridge, Massachusetts, is a pioneering biopharmaceutical company dedicated to developing novel treatments in oncology and hematology. With a strong focus on gene regulation and RNA-based therapies, Syros has established itself as a leader in precision medicine. The company leverages its proprietary platform to identify and target the root causes of diseases, offering hope to patients with high unmet medical needs. Syros Pharmaceuticals Inc. has earned a stellar market reputation, recognized by industry analysts and peers for its scientific rigor and strategic partnerships. The company’s integrated approach combines cutting-edge research, robust clinical development, and patient-centric values, making it a top-tier employer in the Healthcare sector.

Syros Pharmaceuticals Inc. operates at the intersection of genomics and drug discovery, with a pipeline that includes multiple clinical and preclinical candidates. The company’s flagship programs target key transcription factors and epigenetic regulators, areas that have historically been difficult to address. By harnessing the power of RNA, Syros is unlocking new therapeutic avenues. The organization has grown from a small startup to a publicly traded entity (NASDAQ: SYRS), with a market capitalization in the hundreds of millions. Its workforce comprises over 200 employees, including world-class scientists, clinicians, and business professionals. Syros collaborates with top academic institutions and pharmaceutical giants, underscoring its credibility and reach. For professionals seeking to make a tangible impact on patients’ lives, Syros Pharmaceuticals Inc. represents an exceptional career destination.

Company History and Business Evolution (450+ Words)

Syros Pharmaceuticals Inc. was founded in 2011 by a team of renowned scientists from the Broad Institute and MIT, including Dr. Robert J. Gould and Dr. Nathalie Franchimont. The founding vision was to decode the regulatory genome and translate that knowledge into transformative medicines. In its early years, Syros focused on developing its proprietary gene control platform, which maps the regulatory regions of the genome that control gene expression. The company secured significant venture capital funding, including Series A and B rounds from investors like Flagship Pioneering, ARCH Venture Partners, and GV. In 2016, Syros went public on the NASDAQ under the ticker SYRS, raising $60 million in its IPO. This milestone accelerated clinical development of its lead candidate, SY-1425 (tamibarotene), for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Syros achieved several key milestones: initiation of Phase 2 trials for SY-1425 in 2017, expansion into solid tumors with SY-5609 (a CDK7 inhibitor) in 2018, and a strategic partnership with Incyte Corporation in 2019 to develop novel CDK inhibitors. In 2020, Syros announced positive clinical data for tamibarotene in combination with azacitidine, demonstrating improved response rates in a defined patient subset. The company also expanded its pipeline into inflammatory diseases through its RNA-based platform. Through acquisitions and collaborations, Syros has advanced its technology, including the 2021 acquisition of a novel RNA delivery system from a private biotech. Today, Syros Pharmaceuticals Inc. is on the cusp of becoming a fully integrated biopharmaceutical company, with plans to submit New Drug Applications (NDAs) for its lead assets within two years. The company’s evolution reflects its ability to adapt, innovate, and overcome scientific challenges, solidifying its position as a leader in gene regulation therapeutics.

Syros Pharmaceuticals Inc. at a Glance

• Headquarters: Cambridge, Massachusetts, USA
• Founded: 2011
• CEO: Nancy A. Simonian, M.D. (as of 2025)
• Revenue: $45.2 million (FY 2024)
• Employees: 210+
• Stock Symbol: NASDAQ: SYRS
• Industry: Biotechnology / Pharmaceuticals
• Key Focus: Gene regulation, RNA therapeutics, oncology, hematology
• Pipeline: 3 clinical-stage candidates, multiple preclinical programs
• Platform: Syros Gene Control Platform (GCP)
• Lead Drug: Tamibarotene (SY-1425) for AML/MDS
• Partnerships: Incyte, Roche, Gilead Sciences (past collaborations)
• Clinical Trials: Over 10 active or completed Phase 1/2 trials
• Patent Portfolio: 80+ issued patents globally
• Awards: Fierce 15 (2015), BioWorld Top Biotech (2021)
• Culture: Innovation-driven, patient-centric, collaborative
• Office Locations: Cambridge, MA; additional lab space in Lexington, MA
• Website:syros.com
• Social Media: LinkedIn, Twitter (@syros), YouTube
• Niche: First company to systematically map super-enhancers for drug discovery

Mission, Vision, and Core Corporate Values

Mission: Syros Pharmaceuticals Inc. is dedicated to transforming the lives of patients with devastating diseases by decoding the regulatory genome and delivering innovative RNA-based therapies.

Vision: To become the global leader in gene regulation medicine, creating a world where diseases driven by transcriptional dysregulation are effectively treated or cured.

Core Corporate Values: Syros operates with integrity, scientific excellence, patient centricity, collaboration, and accountability. The company fosters a culture of continuous learning and ethical innovation, ensuring that every decision prioritizes patient safety and regulatory compliance.

Business Strategy and Future Roadmap

Syros Pharmaceuticals Inc. employs a focused differentiation strategy, concentrating on high-value targets within gene regulation. The company’s roadmap includes accelerating pivotal trials for tamibarotene in AML/MDS, expanding its CDK7 inhibitor program into combination therapies, and advancing its RNA platform into inflammatory and autoimmune diseases. By leveraging strategic partnerships for manufacturing and commercialization, Syros aims to become a fully integrated biopharma by 2027. The company also plans to explore gene editing applications using its proprietary delivery technology. Financially, Syros is pursuing non-dilutive funding through government grants and milestone payments from partners. The long-term goal is to establish a sustainable pipeline with two to three marketed products within five years.

Products, Technologies, and Services

Syros Pharmaceuticals Inc. specializes in discovering and developing small-molecule and RNA-based therapeutics that modulate gene expression. Key products include: Tamibarotene (SY-1425) – a selective RARα agonist for AML/MDS; SY-5609 – a CDK7 inhibitor for solid tumors; and SY-2106 – a novel oral formulation for acute promyelocytic leukemia. The company’s core technology, the Gene Control Platform (GCP), integrates genome-wide RNA sequencing, chromatin profiling, and machine learning to identify super-enhancers and regulatory elements. Syros also offers services to academic and industry partners through collaborative research agreements, providing access to its platform for target discovery. Additionally, the company provides clinical development services for co-developed assets.

Industries and Markets Served

Syros Pharmaceuticals Inc. primarily serves the biotechnology and pharmaceutical industries, focusing on oncology, hematology, and inflammatory diseases. Its therapies target patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), breast cancer, lung cancer, and other solid tumors. The company also addresses unmet needs in rare genetic disorders through its RNA platform. Syros collaborates with contract research organizations (CROs), academic medical centers, and large pharma companies to expand its reach. The global market for gene regulation therapeutics is projected to exceed $20 billion by 2030, and Syros is well-positioned to capture significant share.

Leadership and Management Philosophy

The leadership team at Syros Pharmaceuticals Inc. comprises seasoned executives with deep pharmaceutical and biotech experience. CEO Nancy A. Simonian brings over 25 years of expertise in drug development and corporate strategy. The management philosophy emphasizes agility, data-driven decision-making, and empowerment. Leaders foster open communication, encourage risk-taking in research, and maintain a flat organizational structure to accelerate innovation. Syros also prioritizes diversity and inclusion, with 45% of leadership positions held by women. The company’s board includes renowned scientists and industry veterans, ensuring robust governance and strategic guidance.

Corporate Events, Conferences, and Community Engagement

Syros Pharmaceuticals Inc. actively participates in major scientific conferences such as the American Society of Hematology (ASH) Annual Meeting, American Society of Clinical Oncology (ASCO) Annual Meeting, and the RNA Therapeutics Conference. The company hosts webinars and symposia to share clinical data and engage with key opinion leaders. Community engagement includes supporting patient advocacy groups like the Leukemia & Lymphoma Society (LLS) and organizing biotech career fairs for local universities. Syros also runs a corporate social responsibility program focused on STEM education in underserved communities in the Boston area.

Employees and Workplace Culture

Syros Pharmaceuticals Inc. fosters a collaborative, innovative, and inclusive workplace culture. Employees enjoy flexible work arrangements, comprehensive health benefits, stock options, and professional development opportunities. The company has been recognized as a “Best Place to Work” by the Boston Business Journal for three consecutive years. Syros emphasizes work-life balance, with on-site wellness programs, a gym subsidy, and regular team-building activities. The culture is driven by a shared passion for defeating disease, with scientists and clinicians working side-by-side with business professionals. Employee turnover is low, reflecting high job satisfaction. Syros also encourages internal mobility and cross-functional learning.

Job Details & Requirements for this Posting (Detailed)

Position: Senior Director of Clinical Development

Syros Pharmaceuticals Inc. is seeking a visionary leader to oversee late-stage clinical programs in oncology. This role is based in Cambridge, MA, and reports to the Chief Medical Officer. The Senior Director will be responsible for developing clinical strategies, managing study execution, and interacting with regulatory authorities.

Responsibilities:

• Lead cross-functional clinical development teams for one or more pipeline assets.
• Design and implement Phase 2/3 clinical trials, including protocol development and site selection.
• Ensure compliance with GCP, ICH guidelines, and FDA/EMA regulations.
• Prepare and review clinical study reports, regulatory submission documents (IND, NDA, MAA).
• Collaborate with translational medicine, biostatistics, data management, and medical writing.
• Present clinical data at scientific conferences and to external stakeholders.
• Mentor and develop junior clinical staff.

Qualifications:

• M.D. or Ph.D. in life sciences; board certification in oncology or hematology preferred.
• 8+ years of clinical development experience in the pharmaceutical or biotech industry.
• Proven track record of advancing oncology compounds from Phase 1 through registration.
• Strong knowledge of regulatory requirements in the US and EU.
• Excellent communication, leadership, and problem-solving skills.
• Experience with gene regulation or RNA therapeutics is a plus.

Why Candidates Should Join Syros Pharmaceuticals Inc.: This role offers a unique opportunity to shape the future of gene regulation medicine. Syros provides a dynamic environment where scientific rigor meets entrepreneurial spirit. The company offers competitive compensation (salary range $225,000 - $275,000 plus bonus and equity) and a clear path for career progression. Employees contribute directly to life-changing therapies, and the culture values every individual’s impact. Join Syros to be at the forefront of precision medicine.

Customer Reviews and Industry Reputation (1200+ Words)

Syros Pharmaceuticals Inc. enjoys a strong reputation across multiple review platforms. Below is an exhaustive analysis of customer and employee feedback, subdivided by source.

GLASSDOOR

On Glassdoor, Syros Pharmaceuticals Inc. holds a 4.2 out of 5 star rating based on 120+ reviews. Employees praise the collaborative culture, intellectual stimulation, and leadership transparency. Common positive themes include “great science,” “flexible work arrangements,” and “supportive management.” Some negative feedback mentions “high workload” and “limited career growth opportunities” due to the company’s size. However, 90% of employees would recommend Syros to a friend. The CEO approval rating is 82%.

INDEED

Indeed features 85 reviews with an average rating of 4.0 stars. Reviewers highlight the company’s strong mission, friendly co-workers, and autonomy. Several note that the interview process is rigorous but fair. Cons include “bureaucracy in some departments” and “below average pay for senior roles.” Overall, 70% of reviewers say the company’s culture is positive.

GARTNER PEER INSIGHTS

Syros is rated 4.5/5 on Gartner Peer Insights under the category “Biopharmaceutical CDMO Services” (though limited reviews). Clients commend the company’s responsiveness and scientific expertise. One review states: “Syros’s platform is truly innovative; their team goes above and beyond.” The platform has validated Syros as a trusted partner for drug discovery.

TRUSTPILOT

Trustpilot shows a 4.6/5 score from 30+ reviews, mainly from patients and advocacy groups. Patients express gratitude for Syros’s compassionate access programs. A typical review: “Syros gave my father hope when other options failed.” There are isolated complaints about clinical trial enrollment delays, but overall sentiment is overwhelmingly positive.

G2

G2 ratings for Syros’s technology platform (Gene Control Platform) average 4.3/5. Users from academic institutions value the platform’s ease of use and predictive accuracy. Comments include: “An essential tool for anyone studying regulatory genomics.” Some note the platform’s high cost for smaller labs.

GOOGLE REVIEWS

Google reviews for Syros’s Cambridge office average 4.4 stars. Visitors highlight the modern facilities, friendly staff, and community engagement. One review: “Syros open house was impressive – they clearly care about their employees and patients.” Negative remarks focus on parking challenges in Kendall Square.

LINKEDIN REPUTATION

Syros Pharmaceuticals Inc. has over 30,000 followers on LinkedIn. The company is recognized as an industry leader in gene regulation. Employees frequently share positive company updates, and the company’s engagement rate is high. LinkedIn’s “Top Companies” list for biotech often includes Syros. The brand is associated with scientific innovation and corporate responsibility.

Why Organizations Choose Syros Pharmaceuticals Inc.

Organizations partner with Syros Pharmaceuticals Inc. for its unmatched expertise in gene regulation, proprietary platform, and proven clinical execution. The company’s ability to identify super-enhancers and druggable targets reduces the risk of failure in drug development. Additionally, Syros’s collaborative approach and flexible deal structures make it an attractive partner for pharma companies seeking to expand pipelines. Academic institutions value Syros’s commitment to open science and data sharing. Ultimately, choosing Syros means accessing world-class science and a team dedicated to translating discoveries into cures.

Official Contact Information

For inquiries and assistance, please reach out to Syros Pharmaceuticals Inc. using the following contact details:

Address: 620 Memorial Drive, Suite 300, Cambridge, MA 02139, USA
Contact Number: +1 (617) 555-0100
Support Number: +1 (800) 555-0199
Helpdesk Number: +1 (617) 555-0123
Website: https://www.syros.com

Official Social Media Presence

Syros Pharmaceuticals Inc. maintains active social media channels: LinkedIn (linkedin.com/company/syros-pharmaceuticals), Twitter (@syros), YouTube (youtube.com/c/SyrosPharmaceuticals), and Facebook (facebook.com/SyrosPharma). These platforms share career opportunities, scientific breakthroughs, and patient stories. Follow Syros to stay updated on the latest in gene regulation therapeutics.

SEO FAQ Section

Syros Pharmaceuticals Inc. is known for its pioneering work in gene regulation and RNA therapeutics, particularly in oncology and hematology, using its proprietary Gene Control Platform to target super-enhancers.

Syros Pharmaceuticals Inc. is headquartered in Cambridge, Massachusetts, USA, at 620 Memorial Drive.

Syros Pharmaceuticals Inc. is publicly traded on the NASDAQ under the ticker symbol SYRS.

As of 2025, the CEO of Syros Pharmaceuticals Inc. is Nancy A. Simonian, M.D.

For this Senior Director role, Syros Pharmaceuticals Inc. offers a salary range of $225,000 to $275,000, plus bonus and equity.

Syros Pharmaceuticals Inc. has over 210 employees as of 2025.

Syros Pharmaceuticals Inc. has developed tamibarotene (SY-1425) for AML/MDS and SY-5609, a CDK7 inhibitor for solid tumors.

Syros Pharmaceuticals Inc. offers flexible work arrangements, but the Senior Director role is based in Cambridge, MA.

Syros Pharmaceuticals Inc. fosters a collaborative, innovative, and inclusive culture with a strong focus on work-life balance and professional growth.

Based on employee reviews on Glassdoor and Indeed, Syros Pharmaceuticals Inc. is generally considered a great place to work, scoring 4.2/5 on Glassdoor.

Syros Pharmaceuticals Inc. has partnerships with Incyte, Roche, and Gilead Sciences, among others.

The Gene Control Platform is Syros Pharmaceuticals Inc.'s proprietary technology that maps super-enhancers and regulatory elements to identify drug targets.

You can apply through the careers page on the Syros Pharmaceuticals Inc. website or via LinkedIn job postings.

Syros Pharmaceuticals Inc. offers comprehensive health benefits, stock options, flexible work, and professional development opportunities.

Yes, Syros Pharmaceuticals Inc. was named to the Fierce 15 in 2015 and BioWorld Top Biotech in 2021.

Syros Pharmaceuticals Inc. is conducting Phase 2 trials for tamibarotene in AML/MDS and Phase 1 trials for SY-5609 in solid tumors.

Yes, Syros Pharmaceuticals Inc. offers compassionate access and patient support programs through partnerships with advocacy groups.

Syros Pharmaceuticals Inc. aims to transform patients' lives by decoding the regulatory genome and delivering innovative RNA-based therapies.

Syros Pharmaceuticals Inc. supports STEM education, patient advocacy groups, and local biotech career fairs in the Boston area.

Syros Pharmaceuticals Inc. plans to submit NDAs for lead assets by 2027 and expand its pipeline into inflammatory diseases through its RNA platform.

For additional insights on digital marketing and guest posting services that can boost your corporate visibility, visit Order Guest Posting Service from The Oklahoma Times—a premier provider of Paid Guest Posting Sites, Guest Post Backlinks, and Guest Post Service Provider solutions. Whether you need SEO Guest Posting Services, Guest Post Outreach Services, or want to Buy Guest Post Packages, The Oklahoma Times offers competitive Guest Post Packages Pricing. Discover how these services can complement your corporate profile and enhance online authority.